Wire · operational-macro
First Factor XIa inhibitor for stroke prevention in certain high-risk patients gains US FDA approval
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 11 November 2026 · Fusion42 review
The US FDA has approved Sunharbo (asundexian), the first Factor XIa inhibitor in the USA, for secondary stroke prevention in adults at high risk after a mild-to-moderate non-cardioembolic ischemic stroke or high-risk transient ischemic attack when used with antiplatelet therapy.
This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.
◆ ◆ The Wire takeaway
You now face a new competitor with an FDA-approved stroke prevention drug that combines with antiplatelet therapy. If you develop treatments in cerebrovascular disease, this approval reshuffles market opportunities and patient protocols immediately.
◆ Coverage
15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026
◆ Related on Wire
◆ Topics